Semaglutide vs Ozempic vs Wegovy: What's the Difference?

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Semaglutide is the active molecule. Ozempic is the brand name for injectable semaglutide approved for type 2 diabetes. Wegovy is the same molecule at a higher dose (2.4 mg vs 1 mg) approved specifically for weight loss. Rybelsus is the oral form.

The Semaglutide Family: One Molecule, Multiple Brands

The confusion between Semaglutide, Ozempic, and Wegovy is understandable — they are all the same active pharmaceutical ingredient (semaglutide) but differ in their approved indications, doses, and delivery systems. Understanding these distinctions is important for anyone considering GLP-1 receptor agonist therapy.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. GLP-1 is a naturally occurring incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain to reduce hunger. Semaglutide has a half-life of approximately 7 days, making once-weekly dosing possible.

Ozempic: Diabetes Indication

Ozempic is the brand name for injectable semaglutide approved by the FDA in 2017 for the treatment of type 2 diabetes mellitus. Available in doses of 0.5 mg, 1 mg, and 2 mg weekly. While approved for diabetes, it also produces significant weight loss (typically 5–10% of body weight) as a secondary effect, leading to widespread off-label use for weight management.

Wegovy: Weight Loss Indication

Wegovy is the brand name for semaglutide at a higher dose (2.4 mg weekly) specifically approved by the FDA in 2021 for chronic weight management. The STEP clinical trial program demonstrated average weight loss of approximately 15% of body weight over 68 weeks — a level of efficacy previously seen only with bariatric surgery.

Rybelsus: The Oral Option

Rybelsus is the oral formulation of semaglutide, approved for type 2 diabetes in 3 mg, 7 mg, and 14 mg doses taken once daily. It must be taken on an empty stomach with a small amount of water and the patient must wait 30 minutes before eating.

Key Differences Summary

Ozempic: 0.5–2 mg weekly SubQ injection for type 2 diabetes. Wegovy: 2.4 mg weekly SubQ injection for obesity/weight management. Rybelsus: 3–14 mg daily oral tablet for type 2 diabetes. The choice depends on your primary goal, insurance coverage, and preference for injection vs. oral administration.